Security
Atea Pharmaceuticals, Inc. Common Stock · AVIR
AVIRNASDAQCommon stockCurrentCIK 1593899Updated Oct 7, 2026
AVIR price & chart
Loading TradingView…
NASDAQ:AVIR on TradingView ↗About the company
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the FDC regimen of BEM, a nucleotide analog polymerase inhibitor, and RZR, an NS5A inhibitor, to treat HCV. AT-587, a nucleotide analog, is in Phase 1 development for the treatment of HEV. For more information, please visit www.ateapharma.com.
In the news
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 ↗
Seeking Alpha
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch ↗
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript ↗
Recent filings
SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding Atea Pharmaceuticals, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 342,963,000Source | 490,957,000Source | 232,282,000Source | 391,605,000Source | 510,384,000Source | 267,076,000Source | 439,964,000Source | 553,029,000Source | 315,218,000Source | 464,668,000Source | 594,968,000Source | 666,708,000Source |
| Property, Plant and Equipment, NetUSD | 561,000Source | 977,000Source | 249,000Source | 665,000Source | 1,081,000Source | 353,000Source | 769,000Source | 1,185,000Source | 457,000Source | 873,000Source | 1,289,000Source | 1,705,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 77,344,000Source | 98,463,000Source | 76,548,000Source | 87,721,000Source | 243,394,000Source | 79,317,000Source | 119,394,000Source | 160,910,000Source | 95,713,000Source | 64,696,000Source | 143,823,000Source | 188,460,000Source |
| Assets, CurrentUSD | 336,138,000Source | 486,906,000Source | 228,665,000Source | 385,604,000Source | 506,369,000Source | 263,197,000Source | 433,708,000Source | 548,764,000Source | 310,991,000Source | 462,355,000Source | 590,455,000Source | 660,922,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,829,000Source | 4,093,000Source | 9,200,000Source | 5,891,000Source | 4,155,000Source | 7,191,000Source | 8,272,000Source | 7,273,000Source | 9,161,000Source | 7,634,000Source | 12,349,000Source | 14,213,000Source |
| Operating Lease, Right-of-Use AssetUSD | 789,000Source | 1,391,000Source | 320,000Source | 942,000Source | 1,538,000Source | 478,000Source | 1,093,000Source | 1,684,000Source | 634,000Source | 1,243,000Source | 1,828,000Source | 2,389,000Source |
| Other Assets, NoncurrentUSD | 5,475,000Source | 1,683,000Source | 3,048,000Source | 4,394,000Source | 1,396,000Source | 3,048,000Source | 4,394,000Source | 1,396,000Source | 3,136,000Source | 197,000Source | 1,396,000Source | 1,494,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 27,183,000Source | 32,436,000Source | — | 27,189,000Source | 33,914,000Source | — | 28,880,000Source | 48,658,000Source | 39,784,000Source | 25,801,000Source | 39,776,000Source | 26,136,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 78,000Source | 84,000Source | 80,000Source | 81,000Source | 84,000Source | 80,000Source | 85,000Source | 84,000Source | 78,000Source | 84,000Source | 83,000Source | 83,000Source |
| Additional Paid in CapitalUSD | 793,166,000Source | 788,473,000Source | 805,116,000Source | 799,951,000Source | 776,192,000Source | 801,735,000Source | 809,373,000Source | 763,472,000Source | 797,751,000Source | 802,770,000Source | 750,737,000Source | 701,052,000Source |
| Retained Earnings (Accumulated Deficit)USD | -477,702,000Source | -330,677,000Source | -600,942,000Source | -435,653,000Source | -299,526,000Source | -568,009,000Source | -398,492,000Source | -259,004,000Source | -522,569,000Source | -364,220,000Source | -195,835,000Source | -59,879,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 238,000Source | 641,000Source | -96,000Source | 37,000Source | -280,000Source | -97,000Source | 118,000Source | -181,000Source | 174,000Source | 233,000Source | 207,000Source | -684,000Source |
| Stockholders' Equity Attributable to ParentUSD | 315,780,000Source | 458,521,000Source | 204,158,000Source | 364,416,000Source | 476,470,000Source | 233,709,000Source | 411,084,000Source | 504,371,000Source | 275,434,000Source | 438,867,000Source | 555,192,000Source | 640,572,000Source |
| Liabilities and EquityUSD | 342,963,000Source | 490,957,000Source | 232,282,000Source | 391,605,000Source | 510,384,000Source | 267,076,000Source | 439,964,000Source | 553,029,000Source | 315,218,000Source | 464,668,000Source | 594,968,000Source | 666,708,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 20,175,000Source | 25,190,000Source | 28,124,000Source | 20,119,000Source | 26,619,000Source | 33,367,000Source | 21,747,000Source | 41,311,000Source | 39,784,000Source | 18,603,000Source | 32,376,000Source | 18,478,000Source |
| Operating Lease, Liability, CurrentUSD | 832,000Source | 790,000Source | 424,000Source | 821,000Source | 780,000Source | 634,000Source | 811,000Source | 769,000Source | 843,000Source | 800,000Source | 760,000Source | 721,000Source |
| Accounts Payable, CurrentUSD | 3,515,000Source | 5,785,000Source | 10,058,000Source | 8,844,000Source | 5,470,000Source | 9,446,000Source | 7,387,000Source | 21,137,000Source | 12,945,000Source | 4,458,000Source | 4,252,000Source | 2,551,000Source |
| Operating Lease, Liability, NoncurrentUSD | 213,000Source | 1,045,000Source | — | 425,000Source | 1,245,000Source | — | 634,000Source | 1,445,000Source | 0Source | 842,000Source | 1,642,000Source | 2,403,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 329,309,000Source | 482,800,000Source | 219,465,000Source | 379,713,000Source | 502,200,000Source | 256,006,000Source | 425,436,000Source | 541,500,000Source | 301,830,000Source | 454,700,000Source | 578,100,000Source | 646,709,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -45,440,000Source | -34,272,000Source | -158,349,000Source | -168,385,000Source | -135,956,000Source | -115,909,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,729,000Source | 6,951,000Source | 20,720,000Source | 51,767,000Source | 49,428,000Source | 46,718,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,499,000Source | 2,929,000Source | 8,487,000Source | 206,000Source | 1,701,000Source | -1,983,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -6,356,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -46,391,000Source | -30,563,000Source | -132,031,000Source | -135,499,000Source | -85,395,000Source | -120,982,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 29,738,000Source | 85,608,000Source | 188,793,000Source | 56,105,000Source | 40,303,000Source | -455,410,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 1,943,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 746,000Source | 485,000Source | 485,000Source | — | — | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 25,519,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 257,000Source | -347,000Source | -25,745,000Source | 267,000Source | 257,000Source | 370,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -16,396,000Source | 54,698,000Source | 31,017,000Source | -79,127,000Source | -44,835,000Source | -576,022,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 77,344,000Source | 98,463,000Source | 76,548,000Source | 87,721,000Source | 79,317,000Source | 119,394,000Source | 95,713,000Source | 64,696,000Source | 143,823,000Source | 188,658,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,517,000Source | 12,164,000Source | 3,381,000Source | 4,667,000Source | 3,729,000Source | 6,951,000Source | 20,720,000Source | 51,767,000Source | 49,428,000Source | 46,718,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 329,309,000Source | 482,800,000Source | 219,465,000Source | 379,713,000Source | 256,006,000Source | 425,436,000Source | 301,830,000Source | 454,700,000Source | 578,100,000Source | 646,709,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | — | — | — | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 7,220,000Source | 11,043,000Source | 6,949,000Source | 9,070,000Source | 6,874,000Source | 9,457,000Source | 32,863,000Source | 48,849,000Source | 49,919,000Source | 48,714,000Source |
| Income Tax Expense (Benefit)USD | — | — | 196,000Source | 226,000Source | 24,000Source | 207,000Source | 50,000Source | 203,000Source | -6,162,000Source | 925,000Source | 1,018,000Source | -3,590,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,049,000Source | -31,151,000Source | -32,933,000Source | -37,161,000Source | -45,440,000Source | -34,272,000Source | -158,349,000Source | -168,385,000Source | -135,956,000Source | -115,909,000Source |
| Operating ExpensesUSD | — | — | 45,567,000Source | 37,202,000Source | 35,099,000Source | 41,345,000Source | 48,008,000Source | 39,041,000Source | 180,887,000Source | 192,950,000Source | 164,162,000Source | 130,650,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 646,000Source | 646,000Source | 646,000Source | 811,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 871,000Source | — | 58,000Source | — | — | 230,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -45,567,000Source | -37,202,000Source | -35,099,000Source | -41,345,000Source | -48,008,000Source | -39,041,000Source | -180,887,000Source | -192,950,000Source | -164,162,000Source | -130,650,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -41,853,000Source | -30,925,000Source | -32,909,000Source | -36,954,000Source | -45,390,000Source | -34,069,000Source | -164,511,000Source | -167,460,000Source | -134,938,000Source | -119,499,000Source |
| Income Tax Expense (Benefit)USD | — | — | 196,000Source | 226,000Source | 24,000Source | 207,000Source | 50,000Source | 203,000Source | -6,162,000Source | 925,000Source | 1,018,000Source | -3,590,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,049,000Source | -31,151,000Source | -32,933,000Source | -37,161,000Source | -45,440,000Source | -34,272,000Source | -158,349,000Source | -168,385,000Source | -135,956,000Source | -115,909,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.53Source | -0.37Source | -0.41Source | -0.44Source | -0.57Source | -0.4Source | -1.94Source | -2Source | -1.63Source | -1.39Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.53Source | -0.37Source | -0.41Source | -0.44Source | -0.57Source | -0.4Source | -1.94Source | -2Source | -1.63Source | -1.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 79,052,154Source | 84,422,000Source | 80,050,518Source | 83,747,335Source | 79,198,204Source | 85,159,254Source | 81,495,352Source | 84,264,715Source | 83,389,750Source | 83,245,385Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 79,052,154Source | 84,422,000Source | 80,050,518Source | 83,747,335Source | 79,198,204Source | 85,159,254Source | 81,495,352Source | 84,264,715Source | 83,389,750Source | 83,245,385Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 104,000Source | 104,000Source | 416,000Source | 416,000Source | 416,000Source | 260,000Source |
| General and Administrative ExpenseUSD | — | — | 7,220,000Source | 11,043,000Source | 6,949,000Source | 9,070,000Source | 6,874,000Source | 9,457,000Source | 32,863,000Source | 48,849,000Source | 49,919,000Source | 48,714,000Source |
| Interest and Other IncomeUSD | — | — | 3,714,000Source | 6,277,000Source | 2,190,000Source | 4,391,000Source | 2,618,000Source | 4,972,000Source | 16,376,000Source | 25,490,000Source | 29,224,000Source | 11,151,000Source |
| Operating ExpensesUSD | — | — | 45,567,000Source | 37,202,000Source | 35,099,000Source | 41,345,000Source | 48,008,000Source | 39,041,000Source | 180,887,000Source | 192,950,000Source | 164,162,000Source | 130,650,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 646,000Source | 646,000Source | 646,000Source | 811,000Source |
| Research and Development ExpenseUSD | — | — | 38,347,000Source | 26,159,000Source | 28,150,000Source | 32,275,000Source | 41,134,000Source | 29,584,000Source | 148,024,000Source | 144,101,000Source | 114,243,000Source | 81,936,000Source |
Filing attachments
ex99_1.htm · SCHEDULE 13G · 2026-10-06
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Atea Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Ag…
Read attachment ↗d165663dex991.htm · 8-K · 2026-08-12
EX-99.1 2 d165663dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027 AT-587 Phase 1 Clinical Trial Advancing f…
Read attachment ↗d12234dex991.htm · 8-K · 2026-05-12
EX-99.1 2 d12234dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a…
Read attachment ↗avir-ex4_2.htm · 10-K · 2026-03-05
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Atea Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to Atea Pharmaceuticals, Inc. General The following description summarizes some of the terms of our restated certificate of incorporation…
Read attachment ↗d118938dex991.htm · 8-K · 2026-03-05
EX-99.1 2 d118938dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Clas…
Read attachment ↗d800383dex991.htm · 8-K · 2026-01-08
Exhibit 99.1 Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HC…
Read attachment ↗